One key call out is that as soon as the top line results are released (~2 to 2.5 years), assuming it's successful, the market WILL respond VERY positively. The result does not need to be outstanding, it just needs to be mediocre or above to get FDA approval given there's no treatment in market like Trofinetide for Retts at the time.
This is all assuming NEUREN is not getting taken over prior to phase 3 result or FDA approval.
The Whens and Whys of Top Biotech M&A Deals, page-25
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
0.070(0.46%) |
Mkt cap ! $1.940B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $15.28 | $14.96 | $1.989M | 131.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 577 | $15.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.20 | 21 | 1 |
View Market Depth
| Last trade - 11.58am 01/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |